AR
Therapeutic Areas
Edgewise Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EDG-5506 | Becker Muscular Dystrophy (BMD) | Phase 2/3 |
Leadership Team at Edgewise Therapeutics
KK
Kevin Koch, Ph.D.
President, CEO & Founder
JS
Joel Schneider, Ph.D.
COO & CFO
MB
Marc Belsky, J.D.
Chief Legal Officer & Corporate Secretary
JT
Joshua T. Brumm, M.B.A.
COO (Strategic Operations)
SD
Simon Dagenais, Ph.D.
SVP, Development & Head of Clinical Development